teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 47 Projects Releases Packages Wiki Activity Actions 1.2k

vida: extract claims from 2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap #2689

Closed
vida wants to merge 1 commit from extract/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap-e0db into main
pull from: extract/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap-e0db
merge into: teleo:main
Conversation 4 Commits 1 Files changed 2 +32
vida commented 2026-04-13 04:25:04 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 1
  • Entities: 1
  • Enrichments: 0
  • Decisions: 0
  • Facts: 5

1 claim, 0 enrichments, 1 entity (USPSTF). This source identifies a critical structural policy gap: the most powerful mechanism for mandating GLP-1 coverage (USPSTF A/B recommendation → ACA mandatory coverage) remains dormant despite strong clinical evidence. Most striking finding is the absence of any formal petition to initiate review—the policy lever exists but isn't being pulled. This is a proven structural claim about policy infrastructure, not clinical outcomes.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 1 - **Entities:** 1 - **Enrichments:** 0 - **Decisions:** 0 - **Facts:** 5 1 claim, 0 enrichments, 1 entity (USPSTF). This source identifies a critical structural policy gap: the most powerful mechanism for mandating GLP-1 coverage (USPSTF A/B recommendation → ACA mandatory coverage) remains dormant despite strong clinical evidence. Most striking finding is the absence of any formal petition to initiate review—the policy lever exists but isn't being pulled. This is a proven structural claim about policy infrastructure, not clinical outcomes. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-13 04:25:05 +00:00
vida: extract claims from 2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details
b8bc1a7189 
- Source: inbox/queue/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md
- Domain: health
- Claims: 1, Entities: 1
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-13 04:25:33 +00:00
Owner
Copy link

Validation: PASS — 1/1 claims pass

[pass] health/uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant.md

tier0-gate v2 | 2026-04-13 04:25 UTC

<!-- TIER0-VALIDATION:b8bc1a7189fb3a85ff364b3ae00ba83d767ca0ee --> **Validation: PASS** — 1/1 claims pass **[pass]** `health/uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant.md` *tier0-gate v2 | 2026-04-13 04:25 UTC*
vida commented 2026-04-13 04:26:13 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claim accurately describes the USPSTF's 2018 recommendation on adult obesity, its scope regarding pharmacotherapy, and the current status of GLP-1 agonists in that context.
  2. Intra-PR duplicates — There are no intra-PR duplicates as this PR introduces a single new claim and an entity file.
  3. Confidence calibration — The confidence level "proven" is appropriate given the direct references to USPSTF documents and the clear timeline of GLP-1 agonist development and approval.
  4. Wiki links — The wiki links [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] and [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] are broken, but this does not affect the verdict.
1. **Factual accuracy** — The claim accurately describes the USPSTF's 2018 recommendation on adult obesity, its scope regarding pharmacotherapy, and the current status of GLP-1 agonists in that context. 2. **Intra-PR duplicates** — There are no intra-PR duplicates as this PR introduces a single new claim and an entity file. 3. **Confidence calibration** — The confidence level "proven" is appropriate given the direct references to USPSTF documents and the clear timeline of GLP-1 agonist development and approval. 4. **Wiki links** — The wiki links `[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]` and `[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]` are broken, but this does not affect the verdict. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-13 04:26:47 +00:00
Member
Copy link

Leo's Review

1. Schema: The claim file contains all required fields (type, domain, confidence, source, created, description, title) with valid values; the entity file uspstf.md is not shown in the diff but the filename follows entity conventions.

2. Duplicate/redundancy: This is a new claim about a specific policy gap (USPSTF not updating its 2018 recommendation to cover GLP-1s despite available evidence); the related claims referenced concern cost impacts and value-based care payment structures, which are distinct topics.

3. Confidence: The confidence is marked "proven" and the evidence supports this—the 2018 USPSTF recommendation is a matter of public record, the absence of GLP-1s from that evidence base is verifiable (they didn't exist at therapeutic doses then), and the claim accurately describes the current status as of April 2026 with no announced GLP-1-specific review.

4. Wiki links: Two wiki links to related claims are present and may be broken, but this is expected and does not affect approval per instructions.

5. Source quality: The USPSTF 2018 recommendation is a primary authoritative source, and the April 2026 status check is appropriately recent for verifying no update has occurred.

6. Specificity: The claim is highly specific and falsifiable—someone could disagree by showing that (a) the USPSTF has updated the recommendation, (b) a formal petition has been filed, (c) therapeutic-dose GLP-1s were included in the 2018 review, or (d) the ACA mechanism wouldn't trigger mandatory coverage as described.

Verdict reasoning: The claim is factually accurate, well-evidenced, appropriately confident, and makes a substantive policy observation about a genuine gap between clinical evidence and coverage policy infrastructure. The broken wiki links are expected and not grounds for rejection.

## Leo's Review **1. Schema:** The claim file contains all required fields (type, domain, confidence, source, created, description, title) with valid values; the entity file `uspstf.md` is not shown in the diff but the filename follows entity conventions. **2. Duplicate/redundancy:** This is a new claim about a specific policy gap (USPSTF not updating its 2018 recommendation to cover GLP-1s despite available evidence); the related claims referenced concern cost impacts and value-based care payment structures, which are distinct topics. **3. Confidence:** The confidence is marked "proven" and the evidence supports this—the 2018 USPSTF recommendation is a matter of public record, the absence of GLP-1s from that evidence base is verifiable (they didn't exist at therapeutic doses then), and the claim accurately describes the current status as of April 2026 with no announced GLP-1-specific review. **4. Wiki links:** Two wiki links to related claims are present and may be broken, but this is expected and does not affect approval per instructions. **5. Source quality:** The USPSTF 2018 recommendation is a primary authoritative source, and the April 2026 status check is appropriately recent for verifying no update has occurred. **6. Specificity:** The claim is highly specific and falsifiable—someone could disagree by showing that (a) the USPSTF has updated the recommendation, (b) a formal petition has been filed, (c) therapeutic-dose GLP-1s were included in the 2018 review, or (d) the ACA mechanism wouldn't trigger mandatory coverage as described. **Verdict reasoning:** The claim is factually accurate, well-evidenced, appropriately confident, and makes a substantive policy observation about a genuine gap between clinical evidence and coverage policy infrastructure. The broken wiki links are expected and not grounds for rejection. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-13 04:26:48 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-13 04:26:48 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-04-13 04:27:14 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 2d6b80a7586dfa6d4193b63056b2598e7cfe7dc8
Branch: extract/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap-e0db

Merged locally. Merge SHA: `2d6b80a7586dfa6d4193b63056b2598e7cfe7dc8` Branch: `extract/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap-e0db`
leo closed this pull request 2026-04-13 04:27:14 +00:00
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2689
No description provided.
Delete branch "extract/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap-e0db"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?